Swedish Orphan Biovitrum AB (LTS:0MTD) EBIT per Share : kr11.35 (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB EBIT per Share?

Swedish Orphan Biovitrum AB's EBIT per Share for the three months ended in Mar. 2024 was kr3.82. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr11.35.

During the past 12 months, the average EBIT per Share Growth Rate of Swedish Orphan Biovitrum AB was -20.30% per year. During the past 3 years, the average EBIT per Share Growth Rate was -3.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's EBIT per Share or its related term are showing as below:

LTS:0MTD' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55.6 Med: 16.9 Max: 382.7
Current: -3.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Swedish Orphan Biovitrum AB was 382.70% per year. The lowest was -55.60% per year. And the median was 16.90% per year.

LTS:0MTD's 3-Year EBIT Growth Rate is ranked worse than
67.61% of 852 companies
in the Drug Manufacturers industry
Industry Median: 7.95 vs LTS:0MTD: -3.60

Swedish Orphan Biovitrum AB's EBIT for the three months ended in Mar. 2024 was kr1,313 Mil.

Swedish Orphan Biovitrum AB EBIT per Share Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB EBIT per Share Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

14.56

14.99

11.95

12.10

12.47

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															4.77	1.32	1.72	4.49	3.82

Swedish Orphan Biovitrum AB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Swedish Orphan Biovitrum AB's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	4065	/	325.968
=	12.47

Swedish Orphan Biovitrum AB's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1313	/	344.066
=	3.82

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr11.35

Swedish Orphan Biovitrum AB (LTS:0MTD) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Swedish Orphan Biovitrum AB EBIT per Share Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK B6E:Germany B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines